Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat.
This report is concerned with therapeutic studies utilizing new bisphosphonic acids on tumor-induced osteolytic metastases. The bone metastases on SD rats were induced by intraarterial and intraosseous transplantation of Walker carcinosarcoma 256 B ascites cells. The treatment was carried out using disodium-3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP), diglycidyl-[3-(3, 3-bisphosphono-3-hydroxy-propylamino)-2-hydroxypropyl-]urazol++ +-Na2 (DDU) and 1,2,4-triglycidylurazol (TGU). The extent of bone metastases was determined by X-ray on the 5th and 10th days following tumor inoculation, as well as both microradiographically and histologically upon termination of the experiment. High dose DDU produced a clear reduction of the tumor osteolysis, but these positive results were surpassed using APD. The best results were achieved by pretreatment with APD 24 h prior to tumor inoculation.
D000818:Animals; D000970:Antineoplastic Agents; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D002279:Carcinoma 256, Walker / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D004164:Diphosphonates / Q000378:metabolism / Q000627:therapeutic use; D008297:Male; D063065:Organophosphonates / Q000378:metabolism / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000378:metabolism / Q000627:therapeutic use; D000077268:Pamidronate; D051381:Rats; D013997:Time Factors; D014230:Triazoles / Q000378:metabolism / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004164:Diphosphonates; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D014230:Triazoles; C048249:diglycidyl-(3-(3,3-bisphosphono-3-hydroxypropylamino)-2-hydroxypropyl)urazol; C041113:anaxirone; D000077268:Pamidronate